Study on the protective effect of semi-closed-loop precise and strict glycemic control on intraoperative ischemia-reperfusion injury in liver transplantation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045342

Enrollment

Unknown

Registered

2021-04-13

Start date

2021-04-19

Completion date

Unknown

Last updated

2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the protection of graft in liver transplantation

Interventions

Precise dynamic Control Group (S Group):Semi-closed-loop precise dynamic blood glucose management (6.0~7.8 mmol/L)

Traditional Group (T Group):None

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 to 65 years; 2.Body mass index (BMI) 18 to 30 kg/m^2; 3.ASA grade I-III; 4.Orthotopic liver transplantation is planned.

Exclusion criteria

Exclusion criteria: 1.Poor preoperative glycemic control (HbA1c > 8.5%); 2.MELD score > 30; 3.Severe cardiopulmonary disease; 4.Nstable preoperative hemodynamics; 5.Preoperative life support (mechanical ventilation, renal replacement therapy, etc.); 6.Severe infection; 7.Anesthetic drug allergy and patient refusal.

Design outcomes

Primary

Measure	Time frame
Early graft dysfunction;	—

Secondary

Measure	Time frame
Blood glucose;Hemoglobin;Platelet count;Alanine transaminase;Glutamic Oxaloacetic Transaminase;Total bilirubin;Direct bilirubin;Serum albumin;Alkaline phosphatase;?-glutamyl transpeptidase;Serum creatinine;Prothrombin time;Partial thromboplastin time;International Normalized Ratio;Tumor necrosis factor;Intedeukin-6;Interleukin-1ß;Length of ICU-stay;Length of stay;Duration of postoperative mechanical ventilation;Blood sugar variability;Hypoglycemic events;	—

Measure

Time frame

Blood glucose;Hemoglobin;Platelet count;Alanine transaminase;Glutamic Oxaloacetic Transaminase;Total bilirubin;Direct bilirubin;Serum albumin;Alkaline phosphatase;?-glutamyl transpeptidase;Serum creatinine;Prothrombin time;Partial thromboplastin time;International Normalized Ratio;Tumor necrosis factor;Intedeukin-6;Interleukin-1ß;Length of ICU-stay;Length of stay;Duration of postoperative mechanical ventilation;Blood sugar variability;Hypoglycemic events;

—

Countries

China

Contacts

Public ContactGao Zhifeng

Beijing Tsinghua Changgung Hospital

gao79@126.com+86 15801249466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026